HAVN Life enters into distribution agreement with Mycrodose Therapeutics for the US market


The agreement allows HAVN Life to export psilocybin naturally derived from its Jamaica installation and expands the list of supply partners in the US market

VANCOUVER, BC, February 10, 2022 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (ESF: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing the standardized extraction of psychedelic compounds for experimental research as potential APIs to support brain health and cognitive function, is delighted to announce its entry into an exclusive United States distribution agreement (the “Exclusive Distribution Agreement Agreement”) with CaliforniaMycrodose Therapeutics Inc. (“Mycrodose”), a leading US pharmaceutical company specializing in the research and development of advanced drug delivery systems using Schedule I, II and III DEA drugs and other compounds aimed at treat cancer-related conditions, mental illnesses, and cognitive degenerative diseases.

HAVN Life and Mycrodose have entered into an exclusive distribution agreement to facilitate the importation of HAVN Life’s naturally sourced GMP psilocybin into United States for authorized research purposes. The exclusive distribution agreement allows HAVN Life & Mycrodose to provide naturally sourced GMP psilocybin to research institutes/researchers in the United States at competitive prices, which should help alleviate supply chain issues currently faced by researchers who cannot find affordable GMP psilocybin. .

“HAVN Life kicks off 2022 with strong partnerships across our research and retail divisions, and we are very excited to begin filling orders for our research customers with our new US distribution partner, Mycrodose Therapeutics,” said the CEO of HAVN Life, Tim Moore. “We have worked closely with Chad and his team, and are excited about the potential of this partnership.”

Mycrodose is one of the few pharmaceutical companies to be licensed by the United States Drug Enforcement Agency (“DEA”), state of california Attorney General’s Research Advisory Board and the Food & Drug Administration (“FDA”) to import and research six (6) Schedule I, II, and III compounds. In December 2021Mycrodose has added a Schedule I import license that allows the import of psilocybin and Schedule I psilocin.

The DEA Import Authorization gives Mycrodose the ability to import the controlled substance of Psilocybin and Psilocin for the purposes of clinical trials, research and development, for analysis and distribution to its customers for authorized research purposes.

“Our company’s proven ability to navigate the meticulous detail required for DEA and FDA approval of these very difficult licenses has directly contributed to Mycrodose’s ability to lead the US pharmaceutical industry in working with these highly controlled substances. here in United States,” said Chad ConnerCEO of Mycrodose Therapeutics. “This distribution partnership with HAVN Life increases access and ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotechnology company working with this Schedule I compound. Mycrodose is dedicated to advancing research in this area and that’s one of the many ways we help,” he adds.

The interest and demand for psilocybin research in United States at significantly increased in 2021 and continues to exceed supply in 2022. Recently, the Drug Enforcement Agency (DEA) again increased the quota for psilocybin research in the United States, HAVN and Mycrodose have already successfully carried out a first purchase order and delivery of naturally sourced GMP Raw Psilocybin Mushrooms from Jamaica in United Statesand Mycrodose actively processes new requests from DEA-accredited institutions and research organizations.

HAVN Life’s activities in Jamaica are facilitated by strategic partnerships with Well-being hypha and PA Benjamin Manufacturing Company provide facilities for cultivation and processing of psilocybe mushrooms.

For more information on obtaining naturally sourced GMP psilocybin, contact Mycrodose Therapeutics at www.MycrodoseThera.com

On behalf of the Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company that pursues the standardized extraction of psychedelic compounds for experimental research as potential APIs, the development of natural health products and innovative therapies to support brain health and improve mental abilities. the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally occurring psychedelic compounds for experimental research with the goal of defining the future of modern medicine. HAVN Life offers a full line of high-quality mushroom and herbal extracts that help support immune function and promote a healthy lifestyle.

Shop our natural herbal health products and learn more about yourhavnlife.comand follow us on Facebook, Twitter, instagram and Youtube.

About Mycrodose Therapeutics

Mycrodose Therapeutics Inc. is a United States-based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems using DEA Schedule I-III drugs and other compounds to treat cancer-related conditions, mental health, and degenerative cognitive diseases. The company believes that its IP-Protected Sustained Micro-Dosing Technology™ is a smarter, safer approach to delivering pharmaceutical compounds to patients of all ages and enables an expandable and scalable business model.

Forward-Looking Information: This press release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the exclusive distribution agreement, business, products and the future of Mycrodose’s business and the business, products and the future of the company. The business of the business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. These forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by such statements depending, among other things, on the risks that the anticipated benefits of the exclusive distribution agreement are not realized as planned, or not at all, the risks that Mycrodose’s products and plan differ from those indicated in this press release and that Mycrodose will not be able to carry out its business plans as expected and the risks that the Company’s products and plan will differ from those set forth in this press release and the Company may not be able to achieve its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information contained in this press release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements contained in this press release are made as of the date of this press release.

CSE has not reviewed, approved or disapproved of the contents of this press release.

SOURCEHAVN Life Sciences Inc.

For more information: Investor Relations: [email protected] 604 687-7130; Media: [email protected] 647 896-8078


Comments are closed.